Effect of vitamin D on cognitive decline: results from two ancillary studies of the VITAL randomized trial

Jae H Kang, Chirag M Vyas, Olivia I Okereke, Soshiro Ogata, Michelle Albert, I-Min Lee, Denise D'Agostino, Julie E Buring, Nancy R Cook, Francine Grodstein, JoAnn E Manson, Jae H Kang, Chirag M Vyas, Olivia I Okereke, Soshiro Ogata, Michelle Albert, I-Min Lee, Denise D'Agostino, Julie E Buring, Nancy R Cook, Francine Grodstein, JoAnn E Manson

Abstract

Low vitamin D levels have been associated with cognitive decline; however, few randomized trials have been conducted. In a trial, we evaluated vitamin D3 supplementation on cognitive decline. We included participants aged 60+ years (mean[SD] = 70.9[5.8] years) free of cardiovascular disease and cancer in two substudies in the VITAL 2 × 2 randomized trial of vitamin D3 (2000 IU/day of cholecalciferol) and fish oil supplements: 3424 had cognitive assessments by phone (eight neuropsychologic tests; 2.8 years follow-up) and 794 had in-person assessments (nine tests; 2.0 years follow-up). The primary, pre-specified outcome was decline over two assessments in global composite score (average z-scores of all tests); substudy-specific results were meta-analyzed. The pooled mean difference in annual rate of decline (MD) for vitamin D3 versus placebo was 0.01 (95% CI - 0.01, 0.02; p = 0.39). We observed no interaction with baseline 25-hydroxyvitamin-D levels (p-interaction = 0.84) and a significant interaction with self-reported race (p-interaction = 0.01). Among Black participants (19%), those assigned vitamin D3 versus placebo had better cognitive maintenance (MD = 0.04, 95% CI 0.01, 0.08, similar to that observed for Black participants 1.2 years apart in age). Thus, vitamin D3 (2000 IU/day cholecalciferol) supplementation was not associated with cognitive decline over 2-3 years among community-dwelling older participants but may provide modest cognitive benefits in older Black adults, although these results need confirmation.Trial registration ClinicalTrials.gov; VITAL (NCT01169259), VITAL-DEP (NCT01696435) and VITAL-Cog (NCT01669915); the date the registration for the parent trial (NCT01169259) was submitted to the registry: 7/26/2010 and the date of first patient enrollment in either of the ancillary studies for cognitive function in a subset of eligible VITAL participants: 9/14/2011.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Figure 1
Figure 1
(a) Flow of Participants in the VITAL-Cog Ancillary Study to the VITAL Trial. (b) Flow of Participants in the subset of CTSC-Cog participants in the VITAL-DEP Ancillary Study to the VITAL Trial.

References

    1. Annweiler C, et al. Vitamin D and ageing: Neurological issues. Neuropsychobiology. 2010;62:139–150. doi: 10.1159/000318570.
    1. Llewellyn DJ, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch. Intern. Med. 2010;170:1135–1141. doi: 10.1001/archinternmed.2010.173.
    1. Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing "D"ecline? Mol. Aspects Med. 2008;29:415–422. doi: 10.1016/j.mam.2008.05.001.
    1. Slusarczyk J, et al. Nanocapsules with polyelectrolyte shell as a platform for 1,25-dihydroxyvitamin d3 neuroprotection: Study in organotypic hippocampal slices. Neurotox. Res. 2016;30:581–592. doi: 10.1007/s12640-016-9652-2.
    1. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 2002;13:100–105. doi: 10.1016/s1043-2760(01)00547-1.
    1. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J. Inflamm. (Lond.) 2008;5:10. doi: 10.1186/1476-9255-5-10.
    1. Bivona G, et al. Non-skeletal activities of vitamin D: From physiology to brain pathology. Medicina (Kaunas) 2019 doi: 10.3390/medicina55070341.
    1. Bivona G, et al. Standardized measurement of circulating vitamin D [25(OH)D] and its putative role as a serum biomarker in Alzheimer's disease and Parkinson's disease. Clin. Chim. Acta. 2019;497:82–87. doi: 10.1016/j.cca.2019.07.022.
    1. Bivona G, et al. The role of vitamin D as a biomarker in Alzheimer's disease. Brain Sci. 2021 doi: 10.3390/brainsci11030334.
    1. Gambino CM, Sasso BL, Bivona G, Agnello L, Ciaccio M. Aging and neuroinflammatory disorders: New biomarkers and therapeutic targets. Curr. Pharm. Des. 2019;25:4168–4174. doi: 10.2174/1381612825666191112093034.
    1. Bivona G, Gambino CM, Iacolino G, Ciaccio M. Vitamin D and the nervous system. Neurol. Res. 2019;41:827–835. doi: 10.1080/01616412.2019.1622872.
    1. Annweiler C, et al. Dietary intake of vitamin D and cognition in older women: A large population-based study. Neurology. 2010;75:1810–1816. doi: 10.1212/WNL.0b013e3181fd6352.
    1. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly US population. J. Gerontol. A Biol. Sci. Med. Sci. 2011;66:59–65. doi: 10.1093/gerona/glq185.
    1. Tarcin O, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab. 2009;94:4023–4030. doi: 10.1210/jc.2008-1212.
    1. Keisala T, et al. Premature aging in vitamin D receptor mutant mice. J. Steroid. Biochem. Mol. Biol. 2009;115:91–97. doi: 10.1016/j.jsbmb.2009.03.007.
    1. Zou J, et al. Progressive hearing loss in mice with a mutated vitamin D receptor gene. Audiol. Neurootol. 2008;13:219–230. doi: 10.1159/000115431.
    1. Brewer LD, Porter NM, Kerr DS, Landfield PW, Thibault O. Chronic 1alpha,25-(OH)2 vitamin D3 treatment reduces Ca2+-mediated hippocampal biomarkers of aging. Cell Calcium. 2006;40:277–286. doi: 10.1016/j.ceca.2006.04.001.
    1. Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am. J. Clin. Nutr. 2008;87:1080S–1086S. doi: 10.1093/ajcn/87.4.1080S.
    1. Shah I, et al. Low 25OH vitamin D2 levels found in untreated Alzheimer's patients, compared to acetylcholinesterase-inhibitor treated and controls. Curr. Alzheimer Res. 2012;9:1069–1076. doi: 10.2174/156720512803568975.
    1. Wang L, et al. Circulating vitamin D levels and Alzheimer's disease: A mendelian randomization study in the IGAP and UK Biobank. J. Alzheimers. Dis. 2020;73:609–618. doi: 10.3233/JAD-190713.
    1. Sommer I, et al. Vitamin D deficiency as a risk factor for dementia: A systematic review and meta-analysis. BMC Geriatr. 2017;17:16. doi: 10.1186/s12877-016-0405-0.
    1. Aghajafari F, Pond D, Catzikiris N, Cameron I. Quality assessment of systematic reviews of vitamin D, cognition and dementia. BJPsych. Open. 2018;4:238–249. doi: 10.1192/bjo.2018.32.
    1. Dean AJ, et al. Effects of vitamin D supplementation on cognitive and emotional functioning in young adults—A randomised controlled trial. PLoS ONE. 2011;6:e25966. doi: 10.1371/journal.pone.0025966.
    1. Rossom RC, et al. Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. J. Am. Geriatr. Soc. 2012;60:2197–2205. doi: 10.1111/jgs.12032.
    1. Stein MS, Scherer SC, Ladd KS, Harrison LC. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J. Alzheimers Dis. 2011;26:477–484. doi: 10.3233/JAD-2011-110149.
    1. Manson JE, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials. 2012;33:159–171. doi: 10.1016/j.cct.2011.09.009.
    1. Manson JE, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N. Engl. J. Med. 2019;380:23–32. doi: 10.1056/NEJMoa1811403.
    1. Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N. Engl. J. Med. 2019;380:33–44. doi: 10.1056/NEJMoa1809944.
    1. Gutierrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos. Int. 2011;22:1745–1753. doi: 10.1007/s00198-010-1383-2.
    1. Powe CE, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med. 2013;369:1991–2000. doi: 10.1056/NEJMoa1306357.
    1. Canevelli M, et al. Race reporting and disparities in clinical trials on Alzheimer's disease: A systematic review. Neurosci. Biobehav. Rev. 2019;101:122–128. doi: 10.1016/j.neubiorev.2019.03.020.
    1. Manson JE, et al. Vitamin D, marine n-3 fatty acids, and primary prevention of cardiovascular disease current evidence. Circ. Res. 2020;126:112–128. doi: 10.1161/CIRCRESAHA.119.314541.
    1. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J. Clin. Psychiatry. 1987;48:314–318.
    1. Albert M, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int. J. Neurosci. 1991;57:167–178. doi: 10.3109/00207459109150691.
    1. Abraham E, Axelrod BN, Ricker JH. Application of the oral trail making test to a mixed clinical sample. Arch. Clin. Neuropsychol. 1996;11:697–701. doi: 10.1093/arclin/11.8.697.
    1. Bastug G, et al. Oral trail making task as a discriminative tool for different levels of cognitive impairment and normal aging. Arch. Clin. Neuropsychol. 2013;28:411–417. doi: 10.1093/arclin/act035.
    1. Brandt J, Folstein MF. Telephone Interview for Cognitive Status: Professional Manual. Psychological Assessment Resources, Inc; 2003.
    1. Army Individual Test Battery. Manual of Directions and Scoring. (War Department, Adjutant General’s Office, 1944).
    1. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsycholgical Test Battery: Therapy and Clinical Interpretation. Neuropsychological Press; 1985.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin. Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.
    1. Annweiler C, et al. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J. Alzheimers Dis. 2013;37:147–171. doi: 10.3233/JAD-130452.
    1. Annweiler C. Vitamin D in dementia prevention. Ann. NY Acad. Sci. 2016;1367:57–63. doi: 10.1111/nyas.13058.
    1. Bischoff-Ferrari HA, et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: The DO-HEALTH randomized clinical trial. JAMA. 2020;324:1855–1868. doi: 10.1001/jama.2020.16909.
    1. Schietzel S, et al. Effect of 2000 IU compared with 800 IU vitamin D on cognitive performance among adults age 60 years and older: A randomized controlled trial. Am. J. Clin. Nutr. 2019;110:246–253. doi: 10.1093/ajcn/nqz081.
    1. Pettersen JA. Does high dose vitamin D supplementation enhance cognition? A randomized trial in healthy adults. Exp. Gerontol. 2017;90:90–97. doi: 10.1016/j.exger.2017.01.019.
    1. Castle M, et al. Three doses of vitamin D and cognitive outcomes in older women: A double-blind randomized controlled trial. J. Gerontol. A Biol. Sci. Med. Sci. 2020;75:835–842. doi: 10.1093/gerona/glz041.
    1. Jorde R, et al. Vitamin D supplementation has no effect on cognitive performance after four months in mid-aged and older subjects. J. Neurol. Sci. 2019;396:165–171. doi: 10.1016/j.jns.2018.11.020.
    1. Owusu JE, et al. Cognition and vitamin D in older African–American women-physical performance and osteoporosis prevention with vitamin D in older African Americans Trial and Dementia. J. Am. Geriatr. Soc. 2019;67:81–86. doi: 10.1111/jgs.15607.
    1. Lipowski M, et al. Improvement of attention, executive functions, and processing speed in elderly women as a result of involvement in the nordic walking training program and vitamin D supplementation. Nutrients. 2019 doi: 10.3390/nu11061311.
    1. Bikle DD, et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J. Clin. Endocrinol. Metab. 1986;63:954–959. doi: 10.1210/jcem-63-4-954.
    1. Brown LL, et al. The vitamin D paradox in Black Americans: a systems-based approach to investigating clinical practice, research, and public health—Expert panel meeting report. BMC Proc. 2018;12:6. doi: 10.1186/s12919-018-0102-4.
    1. Braun A, Bichlmaier R, Cleve H. Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): Allelic differences of the common genetic GC types. Hum. Genet. 1992;89:401–406. doi: 10.1007/BF00194311.
    1. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): A review of isoelectric focusing studies in human populations. Hum. Genet. 1986;72:281–293. doi: 10.1007/BF00290950.
    1. Cooke NE, Haddad JG. Vitamin D binding protein (Gc-globulin) Endocr. Rev. 1989;10:294–307. doi: 10.1210/edrv-10-3-294.
    1. Byrn MA, Adams W, Penckofer S, Emanuele MA. Vitamin D supplementation and cognition in people with type 2 diabetes: A randomized control trial. J. Diabetes Res. 2019;2019:5696391. doi: 10.1155/2019/5696391.
    1. Moore CE, Murphy MM, Holick MF. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J. Nutr. 2005;135:2478–2485. doi: 10.1093/jn/135.10.2478.
    1. Holick MF. Bioavailability of vitamin D and its metabolites in black and white adults. N. Engl. J. Med. 2013;369:2047–2048. doi: 10.1056/NEJMe1312291.
    1. Harris SS. Vitamin D and African Americans. J. Nutr. 2006;136:1126–1129. doi: 10.1093/jn/136.4.1126.
    1. Kang, J. H. et al. Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. Accepted abstract #55393 at the 2021 Alzheimer’s Association International Conference.
    1. Okereke OI, et al. Effect of long-term vitamin d3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2020;324:471–480. doi: 10.1001/jama.2020.10224.
    1. Evans DA, Grodstein F, Loewenstein D, Kaye J, Weintraub S. Reducing case ascertainment costs in US population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2. Alzheimers Dement. 2011;7:110–123. doi: 10.1016/j.jalz.2010.11.008.
    1. Rapp SR, et al. Validation of a cognitive assessment battery administered over the telephone. J. Am. Geriatr. Soc. 2012;60:1616–1623. doi: 10.1111/j.1532-5415.2012.04111.x.
    1. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Wiley; 2004. pp. 103–139.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi